You just read:

Novartis presents updated data that reinforce the efficacy and safety of Kisqali® (ribociclib) plus letrozole as a first-line option for HR+/HER2- advanced or metastatic breast cancer

News provided by

Novartis

Jun 02, 2017, 07:15 ET